Tod Woolf, Ph.D. President and CEO said, "We would like to thank Steve for his leadership and important contributions as RXi expanded its operations, became a public company in early 2008 and closed subsequent rounds of financing. We wish Steve well in his future endeavors."
The Company will be recruiting a new Chief Financial Officer. Read More | Learn about RXII | Corporate Filings Additionally, RXi Pharmaceuticals reported results for the second quarter ended June 30, 2009.
Highlights:
- RXi exercised its option to an exclusive worldwide license to proprietary self-delivery RNAi technology from Advirna LLC – RXi’s assessment of this novel technology indicated that it could enable the delivery of RNAi molecules to cells spontaneously upon direct administration, both in vitro and in vivo, without requiring a delivery vehicle or transfection formulation. The ability to create self-delivering RNAi therapeutics may potentially provide significant competitive advantages in efficacy, toxicity, ease of administration and manufacturing cost. RXi has integrated this technology into its comprehensive delivery platform to develop a sustainable pipeline of products for unmet medical needs.
- $8 Million Public Offering - RXi raised $8 million in a public offering to institutional investors that will be used for working capital and for general corporate purposes.
No comments:
Post a Comment